percentage (p = 0.0002) and higher CrCl/GFR cysC-creat ratio (p = 0.006). By ROC analysis, the CrCl/GFR cysC-creat ratio threshold predicting severe thrombocytopenia was 1.23. Conclusions A low LBM percentage increases the risk of inadequate GFR calculation by CG formula, and carboplatin overdosage with severe thrombocytopenia. High CrCl/ GFR cysC-creat ratio allows the identification of these patients.
Introduction
Renal function evaluation in cancer patients is a major clinical issue, especially in those receiving anticancer drug with low therapeutic index and renal clearance. In daily clinical practice, the renal function is evaluated by the estimation of glomerular filtration rate (GFR) to dose medications [1] .
In 1989, Calvert et al. [2] demonstrated that carboplatin clearance is directly correlated with GFR. They proposed an equation to calculate individual carboplatin dose according to the targeted carboplatin area under the curve (AUC) and the GFR measured by the 51 Cr EDTA clearance. Because the GFR measurement with a radiolabeled isotope is expensive and not readily available, most oncologists use the Cockcroft-Gault formula (CG) to estimate creatinine clearance (CrCl) which is substituted for GFR in the modified Calvert formula for carboplatin dose adaptation. The CG formula takes into account weight, age, and sex as indirect muscle mass markers, in addition to serum creatinine. Indeed, serum creatinine level is not only influenced by the glomerular filtration of creatinine but also by its production, which is related to the total muscle mass [3] .
Several other equations to estimate GFR or CrCl have been proposed (CKD-EPI, Jelliffe, MDRD, etc.). However, they did not appear more predictive to calculate the dose of carboplatin [4] .
In cancer patients, malnutrition and hypercatabolism are common conditions which could be associated with a decrease of total muscle mass and sarcopenia. These situations could lead to serum creatinine decrease, overestimation of CrCl, miscalculation of carboplatin dose, and could increase the risk of severe toxicities. However, there is no reproducible method to detect these patients in routine clinical practice.
Cystatin C has a constant production by all nucleated cells and renal elimination by glomerular filtration. Converse to creatinine, cystatin C level seems to be less affected by muscle mass, albeit it could be modified in case of thyroid dysfunction or corticosteroid use [5] . In noncancer patients, serum cystatin C has been considered to be a better marker of GFR than serum creatinine [6] . Numerous formulas estimating GFR by cystatin C level have been developed. Inker et al. have developed a formula including creatinine and cystatin C level (GFR cysC-creat ), using a large dataset [7] .
In this study, we investigate the influence of total LBM and LBM percentage on GFR calculation, using creatinine (CG equation) or cystatin C (CKD-EPI creatinine-cystatin equation) in cancer patients. Finally, we examined in the subgroup of patients treated with carboplatin, the relation between high CrCl/GFR cysC-creat ratio and the risk of severe thrombocytopenia and propose a new simple index to identify patients at high risk of carboplatin over dosage using the modified Calvert equation.
Materials and methods

Patients
In this observational study, all consecutive cancer patients anticipating receipt of anticancer therapies from July 2010 to October 2014 in the oncology department of Cochin Hospital in Paris, France, were screened. Only patients fully evaluable for CrCl, GFR cysC-creat and LBM measurement were included.
Only patients with GFR cysC-creat > 30 mL/min were kept for total LBM and creatinine or cystatin C plasma level analyses, since it was unlikely that there was a correlation between GFR cysC-creat or CrCl and body composition in patients with severe renal deficiency.
A subgroup of patients treated with carboplatin AUC 5, alone or associated with paclitaxel, was considered for the toxicity analysis.
This study was in compliance with the Declaration of Helsinki and approved by the local medical ethical board. All patients gave their informed consent to LBM measurement and medical data collection.
Anthropometric measurements
Weight and height were measured before the beginning of the treatment at the same date by the hospital staff (medical balance beam scale and stadiometer).
The body mass index (BMI) was calculated according to the equation [weight (kg)/height 2 (m 2 )] and BMI categories were as follows (World Health Organization): underweight (BMI <18.5); normal (18.5-24.9); overweight (25.0-29.9), and obese (≥30).
Body surface area (BSA) (m 2 ) was calculated using the Du Bois formula: 0.007184 × height (cm) 0.725 × weight (kg) 0.425 [8] .
Image analysis
Body composition was evaluated by assessing muscle tissue areas on CT-scan images [9, 10] . CT scans which have been performed for diagnostic or follow-up purposes no more than 30 days before anthropometric and biochemical evaluations were used. Images were analyzed using ImageJ software v1.6.0 (National Institutes of Health, http://rsb. info.nih.gov/ij). The third lumbar vertebra (L3) was chosen as a standard landmark [11] . Muscles were identified based on their anatomic features. The structure of those specific muscles was quantified based on pre-established thresholds of skeletal muscle tissue (−29 to +150 Hounsfield units) [10] . Cross-sectional areas (cm 2 ) of the sum of all of these muscles were computed and the mean value for two consecutive images was computed for each patient. These values were normalized for stature [12, 13] and expressed in units of cm 2 /m 2 . The sex-specific cutoff values for sarcopenia (55.4 cm 2 /m 2 for males and 38.9 cm 2 /m 2 for females) previously determined in cancer patients were used [11] . The total lean body mass (LBM) was estimated from muscle cross-sectional areas [12, 14] : total LBM (kg) = 0.30 × (skeletal muscle area at L3 using CT (cm 2 )) + 6.06. LBM percentage was estimated using the formula: LBM percentage (%) = (LBM (kg)/total body mass (kg)) × 100.
Blood biochemical parameters
Measures of fasting plasma creatinine, fasting plasma cystatin C levels and thyroid-stimulating hormone (TSH-US) were routinely performed in all new patients receiving new anticancer treatment and were done the same day. Pretreatment serum creatinine level was measured by a traceable Jaffe method (Roche Diagnostics, Mannheim, Germany).
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The creatinine assay was IDMS-aligned. Pretreatment cystatin C plasma level was measured by the particle enhanced nephelometric immunoassay (PENIA) method using BN II analyzer (Siemens Healthcare, Erlangen, Germany). The cystatin assay was standardized to ERM-DA471/IFCC.
The CG formula was used for the estimation of CrCl (ml/min): A × weight (kg) × (140 − age (years))/serum creatinine (µmol/l), where A is 1.23 or 1.04 for male and female, respectively. , where κ is 0.9 for males and 0.7 for females, α is s −0.207 for males and −0.248 for females, min indicates the minimum of serum creatinine/κ or 1, and max indicates the maximum of serum creatinine/κ or 1 [7] . GFR cysC-creat has to be adjusted for 1.73 m 2 for comparison with CrCl. This adjustment was defined by GFR cysC-creat × BSA/1.73 [15] .
CrCl/GFR cysC-creat ratio was defined by (CrCl)/ (GFR cysC-creat × BSA/1.73) [15] .
Severe thrombocytopenia assessment in patients receiving carboplatin
Carboplatin dose was calculated with the modified Calvert formula: carboplatin dose (mg) = targeted AUC × (CrCl + 25), where CrCl is calculated with the CG equation.
Only patients receiving carboplatin with a targeted AUC of 5 mg/ml min every three weeks, alone or associated with paclitaxel were included in the toxicity analysis. The patients received paclitaxel according to two different schedules: 80 mg/m 2 D1, D8 and D15 or 175 mg/m 2 D1. The toxicities were assessed during the entire length of the chemotherapy. Blood tests were systematically performed the day before a new chemotherapy administration (weekly paclitaxel: the day before D1, D8, and D15 and three weekly paclitaxel: the day before a new cycle). Blood tests were also performed when clinically indicated, i.e., in case of fever or bleeding.
Severe thrombocytopenia was defined as grade 3-4 according to the NCI CTC criteria v 4.0.
Carboplatin AUC5 dose calculation with several methods
We had compared carboplatin dose received and carboplatin dose calculated with different methods: creatinine cutoff (70 µmol/l), GFR cysC-creat formula, and Schmitt formula.
The different carboplatin clearance (ml/min) formulas are explained below:
Carboplatin clearance calculated with creatinine cutoff is defined by: modified Calvert formula using a rounded creatinine value based on threshold 70 µmol/l for patients with creatinine values below this threshold to estimate CrCl.
Carboplatin clearance calculated with GFR cysC-creat is defined by: modified Calvert formula using GFR cysC-creat to estimate GFR.
Schmitt formula [16] A , with serum creatinine in μmol/L, cysC in mg/l, weight in kilograms, age in years, and A = 0 for male and 1 for female.
Statistical analysis
Results were expressed as mean ± standard deviation (SD) for continuous variables. Comparisons of continuous variables (CrCl and GFR cysC-creat ) and their ratio between LBM quartiles were done using Wilcoxon test statistics. p values <0.05 were considered significant. Correlations between continuous variables were evaluated by Pearson's correlation coefficient.
The relation between biochemical and anthropometric parameters and the occurrence of limiting toxicities was evaluated with univariate subgroup analysis, using Chi square statistics for qualitative variables and Wilcoxon test for continuous variables.
A receiver operating characteristic curve (ROC) was built using the CrCl/GFR cysC-creat ratio as a predictive tool of limiting toxicity. The score threshold was determined by optimization of the sum (sensitivity + specificity).
Comparison between several carboplatin dose calculations-creatinine cutoff (70 µmol/l), GFR cysC-creat formula, and Schmitt formula-to carboplatin dose administrated were done using Wilcoxon test statistics. p values <0.05 were considered significant.
Results
Patients
From July 2010 to October 2014, 134 patients in whom CT scan, serum creatinine level and serum cystatin C levels were done within 30 days before treatment were evaluable. Baseline characteristics of these remaining patients are described in Table 1 . Normal thyroid function was verified before chemotherapy in all patients. The cystatin dosage was performed before the patient received the first cycle of 1 3 chemotherapy and corticosteroid is usually administered with the chemotherapy.
Most patients received cytotoxic chemotherapy (113, 84.3%), while 3 and 13 patients received hormonotherapy (2.2%) or targeted therapy (9.7%), respectively. Five did not receive any anticancer therapy (3.7%). Forty-nine patients (36.6%) were treated with carboplatin-based chemotherapy. Among them, 24 patients were treated with carboplatin AUC 5 alone or associated with paclitaxel.
Total LBM and creatinine and cystatin C plasma levels
In the whole population, mean CrCl and GFR cysC-creat adjusted for 1.73 m 2 was 84.2 ml/min and 79.5 ml/min, respectively.
Among patients with a GFR cysC-creat >30 ml/min (131 patients), those in the highest LBM quartile have a significantly higher creatinine plasma level than those in the lowest quartile (p < 0.005) (Fig. 1) . Thus, low total LBM was correlated with lower serum creatinine level (r = 0.30, p < 0.005). However, low total LBM was also correlated with lower CrCl (r = 0.48, p < 0.005). These data suggested that a low LBM did not lead to CrCl overestimation using CG formula.
Cystatin C plasma level was similar through all LBM quartiles (p = 0.48), confirming that cystatin C plasma level is not correlated with muscular mass (Fig. 1) .
Relation between the percentage of LBM and GFR estimated by creatinine or cystatin C
In the whole population (134 patients), CrCl and GFR cysC-creat were highly correlated (r = 0.86; p < 0.005). However, the CrCl was significantly higher than GFR cysC-creat in patients with the lowest quartile of LBM percentage (p < 0.005). Consequently, LBM percentage was inversely correlated with CrCl/GFR cysC-creat ratio (r = −0.30, p < 0.005) (Fig. 2) .
CrCl was not significantly higher than GFR cysC-creat in patients with the highest quartile of weight (p = 0.06). In patients with BMI >25 kg/m 2 , we have the same results, the CrCl/GFR cysC-creat ratio is inversely correlated with LBM percentage (r = −0.40; p < 0.005).
Thus, these results suggest an over estimation of GFR by CG formula in patients with the lowest LBM percentage.
Carboplatin-induced thrombocytopenia, LBM percentage, and CrCl/GFR cysC-creat ratio
Among 24 patients included in the analysis, one received carboplatin alone, while 23 received carboplatin associated with paclitaxel (weekly n = 4 and three weekly n = 19). Six patients experienced severe thrombocytopenia and , where κ is 0.9 for males and 0.7 for females, α is s −0.207 for males and −0.248 for females, min indicates the minimum of serum creatinine/κ or 1, and max indicates the maximum of serum creatinine/κ or 1, GFR cysC-creat is adjusted for 1.73 m 2 ; LBM lean body mass calculated using the formula 0.30 x (skeletal muscle L3 area measured by computed tomography) + 6.06; LBM percentage lean body mass percentage calculated using formula (LBM (kg)/weight (kg)) × 100; Skeletal muscle L3 index calculated using skeletal muscle L3 area measured by computed tomography/height 2 four of them required a platelet transfusion. One also had a febrile neutropenia. All these patients received carboplatin associated with paclitaxel (weekly n = 2 and three weekly n = 4). Patients with severe thrombocytopenia, compared to patients without it, had significantly higher mean BMI (28.7 vs 22.8, p = 0.02), lower mean LBM percentage (49 vs 64%, p = 0.0002) and higher mean CrCl/GFR cysC-creat ratio (1.3 vs 1.0, p = 0.006) ( Table 2) . BMI was >25 kg/m 2 in 83 and 28% of patients with and without severe thrombocytopenia, respectively.
Using the ROC curve (Fig. 3) , the CrCl/GFR cysC-creat ratio threshold predicting severe thrombocytopenia was 1.23 with an area under the curve of 0.87. The sensitivity and specificity were 83 and 89%, respectively. In the whole cohort, 24 patients (18%) had a CrCl/GFR cysC-creat ratio >1.23. Patients treated with carboplatin AUC5 ± paclitaxel with a CrCl/GFR cysC-creat ratio >1.23 experienced significantly and more frequently severe thrombocytopenia than patients with CrCl/GFR cysC-creat ≤1.23 (p = 0.003). These patients with a low LBM percentage had significantly more grade 3-4 thrombocytopenia (p < 0.005). Figure 4 illustrates the distribution of CrCl/GFR cysC-creat ratio, LBM percentage, and severe thrombocytopenia.
Carboplatin dose calculations comparison
We calculate the dose of carboplatin that would have been administered using alternative methods (CG formula with creatinine level cutoff at 70 µM, GFR cysC-creat formula and Schmitt formula) in patients who experienced severe thrombocytopenia and compare it to the dose effectively administered using the CG formula. The dose of carboplatin calculated using GFR cysC-creat formula, Schmitt formula and creatinine level cutoff at 70 µM was lower than the dose administered using CG formula in most patients (the mean decrease is 31, 29, and 10% respectively).
Similarly, GFR cysC-creat and Schmitt formula led to a significant decrease in the carboplatin dose compared with CG formula in patients with high CrCl/GFR cysC-creat ratio (>1.23) (data not shown). 
Discussion
In this study, we demonstrate that CG formula overestimates renal function compared to GFR cysC-creat in patients with low LBM percentage. We strongly suggested that this discrepancy led to increase incidence of carboplatininduced severe thrombocytopenia in patients with low LBM percentage.
In the first step, we confirmed that serum creatinine level is dependent of total LBM in cancer patients. By contrast, the significant decrease of CrCl in patients with low total LBM can be explained by the fact that CG formula takes into account weight, sex, and age, all variables that are associated with muscle mass. This result suggests that low LBM is not associated by itself with a specific risk of CrCl overestimation using CG formula, because the majority of patients in this situation also have a low total weight (lean sarcopenic patients).
We, however, identified a subgroup of patients in whom CG formula appears to overestimate GFR, namely those with abnormal body composition and low LBM percentage. The GFR overestimation was assessed by comparing CrCl and GFR cysC-creat , being considered as the reference method. Indeed, several studies have shown that the evaluation of GFR using serum cystatin C is superior to methods using serum creatinine, especially in sarcopenic patients [6, 17, 18] . The overestimation of GFR by CG formula in patients with low LBM percentage can be explained by the fact that in these patients, the muscle mass is no longer reflected by weight. Many situations could be associated with low LBM percentage in the cancer setting, such as patients with edema or ascites, or those with sarcopenia but with high fat mass (sarcopenic overweight patients).
The clinical importance of our finding is supported by the observation of increased carboplatin-induced grade 3-4 thrombocytopenia in patients with low LBM percentage receiving carboplatin-paclitaxel combination. It is important to note that this increased incidence of thrombocytopenia is observed despite the fact that paclitaxel is known to have a protective effect on the risk of carboplatin-induced thrombocytopenia [19] . This increase in carboplatin toxicity appeared to be related to an excessive exposure to carboplatin due to overestimation of GFR by CG formula. Indeed, the mean ratio CrCl/GFR cysC-creat was significantly higher in patients who experienced severe toxicities compared to those who did not. Interestingly, BMI > 25 kg/m 2 was also associated with severe carboplatin toxicities, suggesting that overweight sarcopenic patients are at a higher risk of carboplatin toxicities.
In routine clinical practice and most clinical trials, the calculation of carboplatin dose is done by the modified Calvert equation, using CG formula. However, this method has shown important limitations in some patient populations. Thus, two carboplatin pharmacokinetics studies showed that the modified Calvert equation with CG formula overestimated carboplatin dose in obese and malnourished cancer patients [20, 21] . In another retrospective study, overweight cancer patients with low creatinine level (<70 µM), an indicator of a low muscular mass, had a mean overestimation of carboplatin dose by 25% using modified Calvert formula compared to the original formula with calculation of CrCl by urine creatinine dosage, while the two formulas gave similar results in the whole population [22] . Taken together these studies supported our finding that patients with low LBM percentage have high risk of carboplatin overdosage when Calvert modified formula is used. Clearly, in those patients who could be easily identified by a high CrCl/ GFR cysC-creat ratio, the use of the modified Calvert equation for the calculation of carboplatin dose should be avoided.
Several methods have been proposed to improve carboplatin dosing in the setting of low LBM percentage. In overweight cancer patients with low creatinine level, the use of adjusted body weight in the CG formula instead of real weight gave a carboplatin dose significantly closest to those obtained with measured CrCl [22] . However, carboplatin toxicities were not assessed in this study. In two other studies, the use of a minimal value of serum creatinine of 70 µmol/l to estimate GFR by CG formula gave conflicting results [20, 23] . Schmitt et al. [16] proposed a new formula for carboplatin dose calculation adding cystatin C to serum creatinine, age, weight and sex. Compared to the observed carboplatin clearance, they found that the new formula allowed to predict carboplatin clearance with an absolute percent error <20% in 75% of patients, compared to 62% using modified Calvert formula. In our cohort, Schmitt formula has allowed to decrease significantly carboplatin dose in patients with thrombocytopenia grade 3-4 than in patients without toxicity. Finally, Chu et al. [24] proposed a new equation for renal function using serum creatinine and muscle surface area evaluated with CT scan which needs further validation for carboplatin dosing. Thus, to date, no formula had proved to decrease the incidence of carboplatin severe toxicities compared to modified Calvert equation. Our results open new opportunities to improve carboplatin therapeutic index.
Indeed, we identified a threshold value of 1.23 for CrCl/ GFR cysC-creat ratio, which is associated with a low LBM percentage and increase toxicity of carboplatin. We propose to assess this simple biological index in all patients before they receive carboplatin. In the majority of patients with CrCl/GFR cysC-creat ratio index <1.23 (82% of patients of our whole cohort), the modified Calvert formula should be used. Conversely, in those with a higher ratio, it could be proposed to measure GFR with a radiolabelled isotope, which remains the reference method with the lowest bias. However, in clinical practice, this measure is not readily available. Alternatively, the Schmitt formula could be used for this patient with a higher CrCl/GFR cysC-creat ratio. This formula allows a homogenous and easy carboplatin dosing. However, our monocentric data need further validation by a larger prospective trial. The cut-off value of 1.23 for CrCl/GFR cysC-creat ratio required prospective evaluation, and comparison with carboplatin clearance (i.e., measure carboplatin AUC) or radionuclide GFR.
In conclusion, estimation of CrCl by modified Calvert formula is inadequate in patients with a low LBM percentage and leads to carboplatin excessive toxicities. The measure of CrCl/GFR cysC-creat ratio is a simple method to detect these patients and propose less biased methods for GFR measurement and carboplatin dose calculation.
